Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. (BSGM) on March 4, 2021, reporting events occurring on that date. The registrant is a Delaware corporation with principal executive offices in Westport, Connecticut. The report focuses on intellectual property developments involving ViralClear Pharmaceuticals, Inc., a majority-owned subsidiary.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a Current Report regarding a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the expansion of the Company's intellectual property portfolio:
- New Patent Allowance: A utility patent (Application No. 16/805,017) titled "Systems and Methods for Electroporation" was allowed. This patent covers methods for treating hypertension via electroporation of nerves in the renal area.
- Portfolio Growth: This allowance brings the total number of allowed/issued patents to nine.
- Pending Applications: The Company has 16 additional worldwide utility patent applications pending for its PURE EP System, two pending U.S. applications for artificial intelligence, and exclusive licenses to 15 additional pending worldwide utility applications from the Mayo Foundation.
- Design Patents: The Company holds 24 allowed worldwide design patents for display screens and graphical user interfaces.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, forward-looking outlook statements, or specific risk factors beyond the general context of patent development. The management commentary is limited to the announcement of the patent allowance and the status of the broader patent portfolio.
Investor Verification Checklist
- Verify the commercial viability and regulatory pathway for the newly allowed hypertension treatment patent.
- Confirm the status and expected issuance dates for the 16 pending utility patent applications related to the PURE EP System.
- Review the terms of the exclusive license agreements with the Mayo Foundation for Medical Education and Research.
- Assess the competitive landscape for renal denervation and electroporation technologies.